Leiomyosarcoma after hysteroscopic myomectomy: a case report

Objectives: The aim of this study was to illustrate the importance of hysteroscopy in the evolution of mitotically active leiomyoma to leiomyosarcoma (LMS). Uterine sarcomas are rare tumors. The three microscopic criteria are: 1) the presence of coagulative tumor necrosis, 2) high mitotic index (exceeding 15 x 10 catabolite gene activator (CGA) and 3) occurrence of moderate to severe cytologic atypia. The authors report a case of a 52-year-old nulliparous woman with a LMS detected two months after a hysteroscopic resection of a mitotically active leiomyoma. After the first hysteroscopic resection the diagnosis was atypical leiomyoma with a mitotic index of two per ten high-power field (hpf) in the absence of coagulation necrosis. After two months, a new myoma was detected and another hysteroscopic resection was performed: the microscopic diagnosis was LMS and a total abdominal hysterectomy with bilateral salpingo-oophorectomy (BSO) was performed. Conclusion: The patient must undergo close clinical and instrumental follow-up procedures. Hysteroscopy plays an important role in the evaluation and evolution of both recurrent and de novo disease.

Leiomyosarcoma; Hysteroscopy

[1] Ueda S.M., Kapp D.S., Cheung M.K., Shin J.Y., Osann K., Husain A. et al.: “Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths”. Am. J. Obstet. Gynecol., 2008, 198, 218.

[2] Wang W.L. et al.: “Histopathologic prognostic factors in Stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases”. Am. J. Surg. Pathol., 2011, 35, 522.

[3] Tavassoli F.A., Devilee P.: “Tumors of the breast and female genital organs”. World Health Organization Classification of Tumours. International Agency for Research on Cancer (IARC), IARC Press, Lyon, 2003.

[4] Kempson R.L., Hendrickson M.R.: “Smooth muscle, endometrial stromal and mixed Müllerian tunors of the uterus”. Mod. Pathol., 2000, 13, 328.

[5] Bansal N., Herzong T.J., Brunner-Brown A., Wethington S.L., Cohen C.J., Burke W.M., Wright J.D.: “The utility of preoperative endometrial sampling for the detection of uterine sarcomas”. Gynecol. Oncol., 2008, 110, 43.

[6] Prat J.: “FIGO staging for uterine sarcomas”. Int. J. Gynecol. Obstet., 2009, 104, 177.

[7] Gadducci A., Cosio S., Romanini A., Gennazzani A.R.: “The management of patients with uterine sarcoma: a debated clinicl challenge”. Crit. Rew. Oncol. Hematol., 2008, 65, 129.

[8] Kim J.H., Choi Y.J., Kim D.C., Lee S.J.: “Leiomyosarcoma arising in a patient with prior mitotically active leiomyoma”. J. Obstet. Gynaecol. Res., 2010, 36, 187.

[9] Giuntoli R.L. 2nd: “Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma”. Gynecol. Oncol., 2007, 106, 82.

[10] Kapp D.S., Shin J.Y., Chan J.K.: “Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy”. Cancer, 2008, 112, 820.

[11] Seddon M.S., Davda R.: “Uterine sarcomas - Recent progress and future challenges”. Eur. J. Radiol., 2011, 78, 30.